Airsonett® is a Swedish medical technology company that is a leader in the non-pharmacological treatment of patients with allergic severe, uncontrolled asthma and eczema. Airsonett® Air4 is a non-invasive medical device for home treatment based on the patented technology Temperature-regulated laminar airflow (TLA). Treatment with Airsonett® Air4 results in a drastic reduction of allergens and other airborne particles in the patient's breathing zone during rest and sleep. Airsonett® Air4 is recommended by the National Board of Health and Welfare and the Swedish Association of Pediatricians and since 2015 has been included in the Swedish Medicines Agency's guidelines for asthma treatment. Airsonett® Air4 is a CE-marked medical device, Class 1, intended to be used for the relief of symptoms in allergic diseases such as allergic asthma and eczema. It complies with relevant EU directives regarding design, function, safety, health requirements and has undergone rigorous clinical research as well as health economic analyses. Airsonett® Air4 holds a 510(k) approval, Class II, from the FDA. The company's main owners are SEB Venture Capital, Industrifonden and Magnus Lundberg. For further information, visit www.airsonett.se